TY - JOUR
T1 - Intravesical gemcitabine in recurrent superficial bladder carcinoma
T2 - Preliminary results on ablative efficacy and tolerability
AU - Campodonico, Fabio
AU - Canepa, Giorgio
AU - Capponi, Giacomo
AU - Bozzo, Luigi
AU - Maffezzini, Massimo
PY - 2005/5
Y1 - 2005/5
N2 - Background: The ablative potential and toxicity of gemcitabine, administered intravesically in low stage and grade superficial transitional cell carcinoma (TCC), were evaluated. Patients and Methods: Patients with a history of recurrent Ta-T1, G1-G2 bladder TCC were considered eligible for the study. Gemcitabine was administered intravesically at 40 mg/mL concentration (2000 mg in 50 ml saline) in one weekly instillation for 4 consecutive weeks. Fifteen days after the last instillation, patients were submitted to transurethral resection (TUR). Results: Twenty-six patients were evaluable for toxicity, and 20 were evaluable for response, 6 patients being excluded due to toxicity. A complete response was achieved by 10 out of 20 patients (50%), whereas no response was documented in the remainder. Toxicity leading to treatment interruption was grade 3 in 1 patient and grade 2 in 5 patients. Conclusion: Intravesical gemcitabine administered at 40 mg/mL showed the capability of ablating small volume, superficial TCC in 50% of the population under study, with acceptable tolerability.
AB - Background: The ablative potential and toxicity of gemcitabine, administered intravesically in low stage and grade superficial transitional cell carcinoma (TCC), were evaluated. Patients and Methods: Patients with a history of recurrent Ta-T1, G1-G2 bladder TCC were considered eligible for the study. Gemcitabine was administered intravesically at 40 mg/mL concentration (2000 mg in 50 ml saline) in one weekly instillation for 4 consecutive weeks. Fifteen days after the last instillation, patients were submitted to transurethral resection (TUR). Results: Twenty-six patients were evaluable for toxicity, and 20 were evaluable for response, 6 patients being excluded due to toxicity. A complete response was achieved by 10 out of 20 patients (50%), whereas no response was documented in the remainder. Toxicity leading to treatment interruption was grade 3 in 1 patient and grade 2 in 5 patients. Conclusion: Intravesical gemcitabine administered at 40 mg/mL showed the capability of ablating small volume, superficial TCC in 50% of the population under study, with acceptable tolerability.
KW - Gemcitabine
KW - Intravesical chemotherapy
KW - Superficial bladder cancer
UR - http://www.scopus.com/inward/record.url?scp=22944457883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22944457883&partnerID=8YFLogxK
M3 - Article
C2 - 16080464
AN - SCOPUS:22944457883
VL - 25
SP - 2381
EP - 2384
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 3 C
ER -